Skip to main content
Clinical Trials/KCT0003814
KCT0003814
Terminated
未知

High Density Spinal Cord Stimulation for the Treatment of Chronic Intractable Pain Patients: A Prospective Multicenter Randomized Controlled, Double-blind, Crossover Exploratory Study with 6-m Open Follow-up

Seoul National University Hospital0 sites100 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Symptoms, signs and abnormal clinical and laboratory findings, NEC
Sponsor
Seoul National University Hospital
Enrollment
100
Status
Terminated
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
April 15, 2019
Last Updated
last year
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • (1\)Patients with chronic intractable pain who meets the Korean SCS Reimbursement Guideline as follows:
  • (Korea SCS Reimbursement Guideline)
  • a)An ineffective patient with sustainable severe intractable pain (VAS or NRS pain score over 7 grade) who has been treated by a conservative therapy (medication and nerve block, etc.) for 6 months.
  • cf.) CRPS is available after the conservative therapy for 3 months
  • b)An ineffective cancer pain patient with over 1 year life expectancy and VAS (or NRS pain score) over 7 grade who takes active pain treatment for 6 months such as medication, nerve block, epidural morphine injection, etc.
  • (2\)Age \> 18
  • (3\)Patients who have been informed of the study procedures and has given written informed consent.
  • (4\)Patients who are willing to comply with study protocol including attending the study visits

Exclusion Criteria

  • (1\)Expected inability of patients to receive or properly operate the SCS system
  • (2\)Active malignancy
  • (3\)Addiction to any of the following drugs, alcohol, and/or medication
  • (4\)Evidence of an active disruptive psychiatric disorder or other known condition significant enough to impact perception of pain, compliance to intervention and/or ability to evaluate treatment outcome as determined by investigator
  • (5\)Local infection or other skin disorder at site of incision
  • (6\)Pregnancy
  • (7\)Other implanted active medical device
  • (8\)Life expectancy \< 1 year
  • (9\)Coagulation deficiency (Platelet count \< 100,000, PT INR \> 1\.4\)
  • (10\)Immune deficiency (HIV positive, immunosuppressive, etc.)

Outcomes

Primary Outcomes

Not specified

Similar Trials